- Sai Life Sciences has completed Phase II of Production Block 11 at its Bidar site, India, expanding total installed reactor capacity to around 700 KL.
- The facility, inspected by global regulators, specialises in API and intermediate production for highly regulated markets.
Sai Life Sciences Limited, a contract research, development, and manufacturing organisation (CRDMO), has completed Phase II of its new Production Block 11 (PB-11) at its flagship API manufacturing facility in Bidar, India. The expansion increases the block’s combined reactor capacity to approximately 200 KL, making it the largest at the site.
The development adds to the company’s overall reactor capacity at Bidar, which now stands at around 700 KL. Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. Phase II, adding roughly 91 KL, was completed in Q1 FY26.
PB-11 is designed as a multi-purpose production block for large-scale commercial products. Sai Life Sciences said the expansion strengthens its ability to support client programmes through enhanced API and intermediate manufacturing. Krishna Kanumuri, CEO and Managing Director, commented: “This expansion at Bidar is more than additional capacity — it is about giving our partners the confidence that we can scale with their needs, deliver reliably, and adapt to the increasing complexity of their programs.”
The Bidar Unit IV site comprises 12 production blocks with a combined capacity of around 700 KL, facilities for high-potency APIs, advanced quality control laboratories, and capabilities including lyophilisation, cryogenic reactions, high-pressure reactions, and commercial-scale chromatography.
The facility has been inspected and approved by regulatory agencies such as the US FDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life Sciences reported that its manufacturing units had undergone more than 75 customer audits in the past three years, reflecting its emphasis on quality, safety, and compliance.
